No Data
Jilin Aodong Pharmaceutical Group (000623.SZ): Currently, the production of Oseltamivir phosphate capsules is normal and can meet the medication needs of the general public.
On January 7th, GiLonghui reported that Jilin Aodong Pharmaceutical Group (000623.SZ) stated on the investor interaction platform that recently, with the high incidence of influenza, the company produces Oseltamivir phosphate capsules in three specifications of 45mg, 30mg, and 75mg, which are used for the treatment of Type A and Type B influenza in adults and children aged 1 year and older, as well as for the prevention of Type A and Type B influenza in adults and adolescents aged 13 and above. It is a preferred medication Against Influenza. Currently, the company's production of Oseltamivir phosphate capsules is normal and can meet the medication needs of the general public.
Jilin Aodong Pharmaceutical Group (000623.SZ): Yanbian Pharmaceutical's product Xuefu Zhuyu oral liquid is expected to be selected for centralized procurement.
On January 3rd, Gelonghui reported that Jilin Aodong Pharmaceutical Group (000623.SZ) announced that its holding subsidiary, Jilin Aodong Yanbian Pharmaceutical Co., Ltd. (referred to as "Yanbian Pharmaceutical"), participated in the centralized bulk procurement of the National Chinese Patent Medicine Procurement Alliance. According to the announcement on December 30, 2024, by the Hubei Medical Insurance Service Platform regarding the "Proposed Selection Results for the Centralized Bulk Procurement of the National Chinese Patent Medicine Procurement Alliance," Yanbian Pharmaceutical's product, Xuefu Zhuyu Oral Liquid, is proposed to be selected for this centralized bulk procurement. In the year 2023, the sales revenue of the company's product, Xuefu Zhuyu Oral Liquid, reached 125.5376 million yuan, accounting for the company's 2023 annual revenue.
Jilin Aodong Pharmaceutical Group (000623.SZ): has cumulatively repurchased 1.36% of shares.
On January 2nd, Gelonghui reported that Jilin Aodong Pharmaceutical Group (000623.SZ) announced that as of December 31, 2024, the company had cumulatively repurchased 16,251,900 shares through its dedicated securities account for share repurchase via centralized bidding, accounting for 1.36% of the company's total share capital of 1,195,895,387 shares as of December 31, 2024, with a maximum Fill Price of 19.21 yuan/share, a minimum Fill Price of 17.70 yuan/share, and a total payment amount of approximately 0.3 billion yuan (excluding transaction costs).
Health Check: How Prudently Does Jilin Aodong Pharmaceutical Group (SZSE:000623) Use Debt?
Jilin Aodong Pharmaceutical Group (000623.SZ): Taonan Pharmaceutical has obtained the pharmaceutical registration certificate for granules.
Gelonghui November 27th | Jilin Aodong (000623.SZ) announced that recently, Jilin Aodong Pharmaceutical Group Co., Ltd., a holding subsidiary of Jilin Aodong Pharmaceutical Group, received the 《Drug Registration Certificate》 of Guanyan Decoction Granules issued by the National Medical Products Administration. The main functions of Guanyan Decoction Granules are nourishing yin and soothing the liver. It is used for liver yin deficiency, blood dryness and qi stagnation syndrome. Symptoms include chest and hypochondriac pain, acid regurgitation, bitter taste in the mouth, dry throat, red and less fluid tongue, and thin and stringy pulse. It is also used to treat hernia and accumulation.
Aodong Pharmaceutical Gets Agricultural Bank of China's Assurance to Receive the 420 Million Yuan Loan
No Data
